CRISPR Technique

The endogenous manufacturing of CRISPR components, through greater research, would make India a commercially successful country in the field of Deep Science, according to Girish Krishnamurthy, CEO & MD, Tata Medical and Diagnostics Ltd.Participating in a panel discussion on 'Gene-Editing On Centre Stage' at the 'Bengaluru Tech Summit 2021', Krishnamurthy opined that the therapeutics R & D is slow in India as compared to the West, hence seeking deeper research experiences is significant."The country also needs to address associated infrastructural issues like the building of cold storage, expanding supply chains and the sorts," he said.The CEO also highlighted the misconception amongst people that CRISPR is meant for therapeutic and not diagnostic purposes and that it needs to change. With basic technology and market being the most crucial focal points, a large number of its applications are to be looked at, serving both urban and rural India.Though grants are channelized ...

The researchers developed the technique using a modified CRISPR-Cas9 system that does not cut the DNA